#begin document (nw/wsj/20/wsj_2078); part 000
nw/wsj/20/wsj_2078   0    0              An    DT  (TOP(S(S(NP*        -    -   -   -       *        (ARG0*         *   (ARG1*   -
nw/wsj/20/wsj_2078   0    1    experimental    JJ             *        -    -   -   -       *             *         *        *   -
nw/wsj/20/wsj_2078   0    2         vaccine    NN             *)       -    -   -   -       *             *)        *        *   -
nw/wsj/20/wsj_2078   0    3             can    MD          (VP*        -    -   -   -       *    (ARGM-MOD*)        *        *   -
nw/wsj/20/wsj_2078   0    4           alter    VB          (VP*     alter  01   1   -       *           (V*)        *        *   -
nw/wsj/20/wsj_2078   0    5             the    DT       (NP(NP*        -    -   -   -       *        (ARG1*         *        *   -
nw/wsj/20/wsj_2078   0    6          immune    JJ             *        -    -   -   -       *             *         *        *   -
nw/wsj/20/wsj_2078   0    7        response    NN             *)       -    -   -   -       *             *         *        *   -
nw/wsj/20/wsj_2078   0    8              of    IN          (PP*        -    -   -   -       *             *         *        *   -
nw/wsj/20/wsj_2078   0    9          people   NNS       (NP(NP*)       -    -   -   -       *             *    (ARG1*)       *   -
nw/wsj/20/wsj_2078   0   10        infected   VBN          (VP*    infect  01   1   -       *             *       (V*)       *   -
nw/wsj/20/wsj_2078   0   11            with    IN          (PP*        -    -   -   -       *             *    (ARG2*        *   -
nw/wsj/20/wsj_2078   0   12             the    DT          (NP*        -    -   -   -       *             *         *        *   -
nw/wsj/20/wsj_2078   0   13            AIDS   NNP             *        -    -   -   -       *             *         *        *   -
nw/wsj/20/wsj_2078   0   14           virus    NN     *)))))))))       -    -   -   -       *             *)        *)       *)  -
nw/wsj/20/wsj_2078   0   15               ,     ,             *        -    -   -   -       *             *         *        *   -
nw/wsj/20/wsj_2078   0   16               a    DT          (NP*        -    -   -   -       *             *         *   (ARG0*   -
nw/wsj/20/wsj_2078   0   17       prominent    JJ             *        -    -   -   -       *             *         *        *   -
nw/wsj/20/wsj_2078   0   18            U.S.   NNP             *        -    -   -   -    (GPE)            *         *        *   -
nw/wsj/20/wsj_2078   0   19       scientist    NN             *)       -    -   -   -       *             *         *        *)  -
nw/wsj/20/wsj_2078   0   20            said   VBD          (VP*)      say  01   -   -       *             *         *      (V*)  -
nw/wsj/20/wsj_2078   0   21               .     .            *))       -    -   -   -       *             *         *        *   -

nw/wsj/20/wsj_2078   0    0    However    RB   (TOP(S(ADVP*)        -    -   -   -   *    (ARGM-DIS*)            *   -
nw/wsj/20/wsj_2078   0    1          ,     ,              *         -    -   -   -   *             *             *   -
nw/wsj/20/wsj_2078   0    2       that    DT           (NP*)        -    -   -   -   *        (ARG0*)            *   -
nw/wsj/20/wsj_2078   0    3       does   VBZ           (VP*         -    -   -   -   *             *             *   -
nw/wsj/20/wsj_2078   0    4        n't    RB              *         -    -   -   -   *    (ARGM-NEG*)            *   -
nw/wsj/20/wsj_2078   0    5       mean    VB           (VP*       mean  01   -   -   *           (V*)            *   -
nw/wsj/20/wsj_2078   0    6       they   PRP    (SBAR(S(NP*)        -    -   -   -   *        (ARG1*        (ARG1*)  -
nw/wsj/20/wsj_2078   0    7        can    MD           (VP*         -    -   -   -   *             *    (ARGM-MOD*)  -
nw/wsj/20/wsj_2078   0    8    benefit    VB           (VP*    benefit  01   -   -   *             *           (V*)  -
nw/wsj/20/wsj_2078   0    9       from    IN           (PP*         -    -   -   -   *             *        (ARG0*   -
nw/wsj/20/wsj_2078   0   10        the    DT           (NP*         -    -   -   -   *             *             *   -
nw/wsj/20/wsj_2078   0   11    vaccine    NN       *))))))))        -    -   -   -   *             *)            *)  -
nw/wsj/20/wsj_2078   0   12          .     .             *))        -    -   -   -   *             *             *   -

nw/wsj/20/wsj_2078   0    0              Its   PRP$       (TOP(S(NP*           -    -   -   -          *        (ARG1*            *        *   -
nw/wsj/20/wsj_2078   0    1    effectiveness     NN                *)          -    -   -   -          *             *)           *        *   -
nw/wsj/20/wsj_2078   0    2               ca     MD             (VP*           -    -   -   -          *    (ARGM-MOD*)           *        *   -
nw/wsj/20/wsj_2078   0    3              n't     RB                *           -    -   -   -          *    (ARGM-NEG*)           *        *   -
nw/wsj/20/wsj_2078   0    4               be     VB             (VP*           -    -   -   -          *             *            *        *   -
nw/wsj/20/wsj_2078   0    5       determined    VBN             (VP*    determine  01   -   -          *           (V*)           *        *   -
nw/wsj/20/wsj_2078   0    6            until     IN           (SBAR*           -    -   -   -          *    (ARGM-TMP*            *        *   -
nw/wsj/20/wsj_2078   0    7                a     DT           (S(NP*           -    -   -   -          *             *       (ARG1*        *   -
nw/wsj/20/wsj_2078   0    8            large     JJ                *           -    -   -   -          *             *            *        *   -
nw/wsj/20/wsj_2078   0    9         clinical     JJ                *           -    -   -   -          *             *            *        *   -
nw/wsj/20/wsj_2078   0   10            trial     NN                *)          -    -   -   -          *             *            *)       *   -
nw/wsj/20/wsj_2078   0   11               is    VBZ             (VP*           -    -   -   -          *             *            *        *   -
nw/wsj/20/wsj_2078   0   12       undertaken    VBN             (VP*    undertake  01   1   -          *             *          (V*)       *   -
nw/wsj/20/wsj_2078   0   13               by     IN             (PP*           -    -   -   -          *             *       (ARG0*        *   -
nw/wsj/20/wsj_2078   0   14              the     DT             (NP*           -    -   -   -          *             *            *        *   -
nw/wsj/20/wsj_2078   0   15             Army    NNP               *))          -    -   -   -       (ORG)            *            *)       *   -
nw/wsj/20/wsj_2078   0   16               in     IN             (PP*           -    -   -   -          *             *   (ARGM-TMP*        *   -
nw/wsj/20/wsj_2078   0   17          January    NNP        (NP*))))))          -    -   -   -      (DATE)            *)           *)       *   -
nw/wsj/20/wsj_2078   0   18                ,      ,                *           -    -   -   -          *             *            *        *   -
nw/wsj/20/wsj_2078   0   19        according    VBG             (PP*           -    -   -   -          *             *            *        *   -
nw/wsj/20/wsj_2078   0   20               to     IN             (PP*           -    -   -   -          *             *            *        *   -
nw/wsj/20/wsj_2078   0   21           Robert    NNP          (NP(NP*           -    -   -   -   (PERSON*             *            *        *   -
nw/wsj/20/wsj_2078   0   22         Redfield    NNP                *)          -    -   -   -          *)            *            *        *   -
nw/wsj/20/wsj_2078   0   23                ,      ,                *           -    -   -   -          *             *            *        *   -
nw/wsj/20/wsj_2078   0   24            chief     NN          (NP(NP*)          -    -   -   -          *             *            *        *   -
nw/wsj/20/wsj_2078   0   25               of     IN             (PP*           -    -   -   -          *             *            *        *   -
nw/wsj/20/wsj_2078   0   26         acquired    VBN     (NP(NML(NML*      acquire  01   -   -          *             *            *      (V*)  -
nw/wsj/20/wsj_2078   0   27           immune     JJ                *           -    -   -   -          *             *            *   (ARG1*   -
nw/wsj/20/wsj_2078   0   28       deficiency     NN                *)          -    -   -   -          *             *            *        *   -
nw/wsj/20/wsj_2078   0   29         syndrome     NN                *)          -    -   -   -          *             *            *        *)  -
nw/wsj/20/wsj_2078   0   30         research     NN               *))    research   -   1   -          *             *            *        *   -
nw/wsj/20/wsj_2078   0   31               at     IN             (PP*           -    -   -   -          *             *            *        *   -
nw/wsj/20/wsj_2078   0   32           Walter    NNP      (NP(NP(NML*           -    -   -   -      (ORG*             *            *        *   -
nw/wsj/20/wsj_2078   0   33             Reed    NNP                *)          -    -   -   -          *             *            *        *   -
nw/wsj/20/wsj_2078   0   34             Army    NNP                *           -    -   -   -          *             *            *        *   -
nw/wsj/20/wsj_2078   0   35        Institute    NNP                *)          -    -   -   -          *             *            *        *   -
nw/wsj/20/wsj_2078   0   36               of     IN             (PP*           -    -   -   -          *             *            *        *   -
nw/wsj/20/wsj_2078   0   37         Research    NNP   (NP*)))))))))))          -    -   -   -          *)            *            *        *   -
nw/wsj/20/wsj_2078   0   38                .      .               *))          -    -   -   -          *             *            *        *   -

nw/wsj/20/wsj_2078   0    0             Dr.   NNP  (TOP(S(NP(NP(NP*      -    -   -   -          *        *        *       (ARG1*   -
nw/wsj/20/wsj_2078   0    1        Redfield   NNP                 *      -    -   -   -    (PERSON)       *        *            *   -
nw/wsj/20/wsj_2078   0    2              's   POS                 *)     -    -   -   -          *        *        *            *   -
nw/wsj/20/wsj_2078   0    3          report    NN                 *)     -    -   -   -          *        *        *            *   -
nw/wsj/20/wsj_2078   0    4              on    IN              (PP*      -    -   -   -          *        *        *            *   -
nw/wsj/20/wsj_2078   0    5           early    JJ           (NP(NP*      -    -   -   -          *   (ARG0*        *            *   -
nw/wsj/20/wsj_2078   0    6     experiments   NNS                 *)     -    -   -   -          *        *)       *            *   -
nw/wsj/20/wsj_2078   0    7           using   VBG              (VP*     use  01   -   -          *      (V*)       *            *   -
nw/wsj/20/wsj_2078   0    8              an    DT           (NP(NP*      -    -   -   -          *   (ARG1*   (ARG1*            *   -
nw/wsj/20/wsj_2078   0    9            AIDS   NNP                 *      -    -   -   -          *        *        *            *   -
nw/wsj/20/wsj_2078   0   10         vaccine    NN                 *)     -    -   -   -          *        *        *)           *   -
nw/wsj/20/wsj_2078   0   11            made   VBD              (VP*    make  01   -   -          *        *      (V*)           *   -
nw/wsj/20/wsj_2078   0   12              by    IN              (PP*      -    -   -   -          *        *   (ARG0*            *   -
nw/wsj/20/wsj_2078   0   13    MicroGeneSys   NNP           (NP(NP*      -    -   -   -      (ORG*        *        *            *   -
nw/wsj/20/wsj_2078   0   14            Inc.   NNP                 *)     -    -   -   -          *)       *        *            *   -
nw/wsj/20/wsj_2078   0   15              of    IN              (PP*      -    -   -   -          *        *        *            *   -
nw/wsj/20/wsj_2078   0   16            West   NNP           (NP(NP*      -    -   -   -      (GPE*        *        *            *   -
nw/wsj/20/wsj_2078   0   17           Haven   NNP                 *)     -    -   -   -          *)       *        *            *   -
nw/wsj/20/wsj_2078   0   18               ,     ,                 *      -    -   -   -          *        *        *            *   -
nw/wsj/20/wsj_2078   0   19           Conn.   NNP    (NP*)))))))))))     -    -   -   -       (GPE)       *)       *)           *)  -
nw/wsj/20/wsj_2078   0   20               ,     ,                 *      -    -   -   -          *        *        *            *   -
nw/wsj/20/wsj_2078   0   21            came   VBD              (VP*    come  01   -   -          *        *        *          (V*)  -
nw/wsj/20/wsj_2078   0   22              at    IN              (PP*      -    -   -   -          *        *        *   (ARGM-TMP*   -
nw/wsj/20/wsj_2078   0   23               a    DT           (NP(NP*      -    -   -   -          *        *        *            *   -
nw/wsj/20/wsj_2078   0   24         meeting    NN                 *)     -    -   -   -          *        *        *            *   -
nw/wsj/20/wsj_2078   0   25              of    IN              (PP*      -    -   -   -          *        *        *            *   -
nw/wsj/20/wsj_2078   0   26            AIDS   NNP          (NP(NML*      -    -   -   -          *        *        *            *   -
nw/wsj/20/wsj_2078   0   27         vaccine    NN                 *)     -    -   -   -          *        *        *            *   -
nw/wsj/20/wsj_2078   0   28     researchers   NNS              *))))     -    -   -   -          *        *        *            *)  -
nw/wsj/20/wsj_2078   0   29              in    IN              (PP*      -    -   -   -          *        *        *   (ARGM-LOC*   -
nw/wsj/20/wsj_2078   0   30         Florida   NNP             (NP*))     -    -   -   -       (GPE)       *        *            *)  -
nw/wsj/20/wsj_2078   0   31            late    JJ              (NP*      -    -   -   -     (DATE*        *        *   (ARGM-TMP*   -
nw/wsj/20/wsj_2078   0   32          Monday   NNP                *))     -    -   -   -          *)       *        *            *)  -
nw/wsj/20/wsj_2078   0   33               .     .                *))     -    -   -   -          *        *        *            *   -

nw/wsj/20/wsj_2078   0    0             The     DT  (TOP(S(NP(NP*            -    -   -   -            *        (ARG1*        *   -
nw/wsj/20/wsj_2078   0    1         vaccine     NN              *)           -    -   -   -            *             *        *   -
nw/wsj/20/wsj_2078   0    2               ,      ,              *            -    -   -   -            *             *        *   -
nw/wsj/20/wsj_2078   0    3          VaxSyn    NNP           (NP*            -    -   -   -    (PRODUCT*             *        *   -
nw/wsj/20/wsj_2078   0    4             HIV    NNP              *            -    -   -   -            *             *        *   -
nw/wsj/20/wsj_2078   0    5              -    HYPH              *            -    -   -   -            *             *        *   -
nw/wsj/20/wsj_2078   0    6              1      CD              *)           -    -   -   -            *)            *        *   -
nw/wsj/20/wsj_2078   0    7               ,      ,              *)           -    -   -   -            *             *)       *   -
nw/wsj/20/wsj_2078   0    8             has    VBZ           (VP*            -    -   -   -            *             *        *   -
nw/wsj/20/wsj_2078   0    9            been    VBN           (VP*            -    -   -   -            *             *        *   -
nw/wsj/20/wsj_2078   0   10          safely     RB         (ADVP*)           -    -   -   -            *    (ARGM-MNR*)       *   -
nw/wsj/20/wsj_2078   0   11           given    VBN           (VP*          give  01   -   -            *           (V*)       *   -
nw/wsj/20/wsj_2078   0   12              to     IN           (PP*            -    -   -   -            *        (ARG2*        *   -
nw/wsj/20/wsj_2078   0   13             14      CD        (NP(NP*            -    -   -   -    (CARDINAL)            *        *   -
nw/wsj/20/wsj_2078   0   14          people    NNS              *)           -    -   -   -            *             *        *   -
nw/wsj/20/wsj_2078   0   15               ,      ,              *            -    -   -   -            *             *        *   -
nw/wsj/20/wsj_2078   0   16            some     DT    (SBAR(WHNP*            -    -   -   -            *             *   (ARG0*   -
nw/wsj/20/wsj_2078   0   17              of     IN         (WHPP*            -    -   -   -            *             *        *   -
nw/wsj/20/wsj_2078   0   18            whom     WP       (WHNP*)))           -    -   -   -            *             *        *)  -
nw/wsj/20/wsj_2078   0   19             are    VBP         (S(VP*            -    -   -   -            *             *        *   -
nw/wsj/20/wsj_2078   0   20    experiencing    VBG           (VP*    experience  01   1   -            *             *      (V*)  -
nw/wsj/20/wsj_2078   0   21     substantial     JJ        (NP(NP*            -    -   -   -            *             *   (ARG1*   -
nw/wsj/20/wsj_2078   0   22       increases    NNS              *)           -    -   -   -            *             *        *   -
nw/wsj/20/wsj_2078   0   23              in     IN           (PP*            -    -   -   -            *             *        *   -
nw/wsj/20/wsj_2078   0   24         certain     JJ           (NP*            -    -   -   -            *             *        *   -
nw/wsj/20/wsj_2078   0   25      antibodies    NNS   *))))))))))))           -    -   -   -            *             *)       *)  -
nw/wsj/20/wsj_2078   0   26               .      .             *))           -    -   -   -            *             *        *   -

nw/wsj/20/wsj_2078   0    0              ``    ``          (TOP(S*        -    -   -   -          *      *        *             *        *   -
nw/wsj/20/wsj_2078   0    1             The    DT           (S(NP*        -    -   -   -          *      *   (ARG1*             *        *   -
nw/wsj/20/wsj_2078   0    2    conventional    JJ                *        -    -   -   -          *      *        *             *        *   -
nw/wsj/20/wsj_2078   0    3          wisdom    NN                *)       -    -   -   -          *      *        *)            *        *   -
nw/wsj/20/wsj_2078   0    4            used   VBN             (VP*       use  03   -   -          *    (V*)       *             *        *   -
nw/wsj/20/wsj_2078   0    5              to    TO           (S(VP*        -    -   -   -          *      *        *             *        *   -
nw/wsj/20/wsj_2078   0    6              be    VB             (VP*        be  01   -   -          *      *      (V*)            *        *   -
nw/wsj/20/wsj_2078   0    7            that    IN           (SBAR*        -    -   -   -          *      *   (ARG2*             *        *   -
nw/wsj/20/wsj_2078   0    8             you   PRP           (S(NP*)       -    -   -   -          *      *        *        (ARG0*)       *   -
nw/wsj/20/wsj_2078   0    9           could    MD             (VP*        -    -   -   -          *      *        *    (ARGM-MOD*)       *   -
nw/wsj/20/wsj_2078   0   10             n't    RB                *        -    -   -   -          *      *        *    (ARGM-NEG*)       *   -
nw/wsj/20/wsj_2078   0   11          modify    VB             (VP*    modify  01   1   -          *      *        *           (V*)       *   -
nw/wsj/20/wsj_2078   0   12             the    DT          (NP(NP*        -    -   -   -          *      *        *        (ARG1*        *   -
nw/wsj/20/wsj_2078   0   13          immune    JJ                *        -    -   -   -          *      *        *             *        *   -
nw/wsj/20/wsj_2078   0   14        response    NN                *)       -    -   -   -          *      *        *             *        *   -
nw/wsj/20/wsj_2078   0   15              of    IN             (PP*        -    -   -   -          *      *        *             *        *   -
nw/wsj/20/wsj_2078   0   16              an    DT             (NP*        -    -   -   -          *      *        *             *        *   -
nw/wsj/20/wsj_2078   0   17        infected    JJ                *        -    -   -   -          *      *        *             *        *   -
nw/wsj/20/wsj_2078   0   18      individual    NN              *)))       -    -   -   -          *      *        *             *)       *   -
nw/wsj/20/wsj_2078   0   19              ''    ''                *        -    -   -   -          *      *        *             *        *   -
nw/wsj/20/wsj_2078   0   20              by    IN             (PP*        -    -   -   -          *      *        *    (ARGM-MNR*        *   -
nw/wsj/20/wsj_2078   0   21    innoculating   VBG           (S(VP*        -    -   -   -          *      *        *             *        *   -
nw/wsj/20/wsj_2078   0   22            them   PRP             (NP*)       -    -   -   -          *      *        *             *        *   -
nw/wsj/20/wsj_2078   0   23            with    IN             (PP*        -    -   -   -          *      *        *             *        *   -
nw/wsj/20/wsj_2078   0   24       synthetic    JJ             (NP*        -    -   -   -          *      *        *             *        *   -
nw/wsj/20/wsj_2078   0   25           viral    JJ                *        -    -   -   -          *      *        *             *        *   -
nw/wsj/20/wsj_2078   0   26        proteins   NNS   *))))))))))))))       -    -   -   -          *      *        *)            *)       *   -
nw/wsj/20/wsj_2078   0   27               ,     ,                *        -    -   -   -          *      *        *             *        *   -
nw/wsj/20/wsj_2078   0   28             Dr.   NNP             (NP*        -    -   -   -          *      *        *             *   (ARG0*   -
nw/wsj/20/wsj_2078   0   29        Redfield   NNP                *)       -    -   -   -    (PERSON)     *        *             *        *)  -
nw/wsj/20/wsj_2078   0   30            said   VBD             (VP*)      say  01   -   -          *      *        *             *      (V*)  -
nw/wsj/20/wsj_2078   0   31               .     .               *))       -    -   -   -          *      *        *             *        *   -

nw/wsj/20/wsj_2078   0   0              ``    ``    (TOP(S*             -    -   -   -   *         *   -
nw/wsj/20/wsj_2078   0   1              We   PRP       (NP*)            -    -   -   -   *    (ARG0*)  -
nw/wsj/20/wsj_2078   0   2             've   VBP       (VP*             -    -   -   -   *         *   -
nw/wsj/20/wsj_2078   0   3    demonstrated   VBN       (VP*    demonstrate  01   1   -   *       (V*)  -
nw/wsj/20/wsj_2078   0   4            that    IN     (SBAR*             -    -   -   -   *    (ARG1*   -
nw/wsj/20/wsj_2078   0   5             you   PRP     (S(NP*)            -    -   -   -   *         *   -
nw/wsj/20/wsj_2078   0   6             can    MD   (VP*)))))            -    -   -   -   *         *)  -
nw/wsj/20/wsj_2078   0   7               .     .          *             -    -   -   -   *         *   -
nw/wsj/20/wsj_2078   0   8              ''    ''         *))            -    -   -   -   *         *   -

nw/wsj/20/wsj_2078   0    0            He   PRP   (TOP(S(NP*)          -    -   -   -   *    (ARG0*)       *        *   -
nw/wsj/20/wsj_2078   0    1          said   VBD         (VP*          say  01   -   -   *       (V*)       *        *   -
nw/wsj/20/wsj_2078   0    2       certain    JJ  (SBAR(S(NP*           -    -   -   -   *    (ARG1*   (ARG1*        *   -
nw/wsj/20/wsj_2078   0    3    volunteers   NNS            *)          -    -   -   -   *         *        *)       *   -
nw/wsj/20/wsj_2078   0    4     developed   VBD         (VP*      develop  01   -   -   *         *      (V*)       *   -
nw/wsj/20/wsj_2078   0    5         kinds   NNS   (NP(NP(NP*)          -    -   -   -   *         *   (ARG2*   (ARG1*   -
nw/wsj/20/wsj_2078   0    6            of    IN         (PP*           -    -   -   -   *         *        *        *   -
nw/wsj/20/wsj_2078   0    7    antibodies   NNS       (NP*)))          -    -   -   -   *         *        *        *)  -
nw/wsj/20/wsj_2078   0    8    associated   VBN         (VP*    associate  01   -   -   *         *        *      (V*)  -
nw/wsj/20/wsj_2078   0    9          with    IN         (PP*           -    -   -   -   *         *        *   (ARG2*   -
nw/wsj/20/wsj_2078   0   10         early    JJ         (NP*           -    -   -   -   *         *        *        *   -
nw/wsj/20/wsj_2078   0   11          AIDS   NNP     *))))))))          -    -   -   -   *         *)       *)       *)  -
nw/wsj/20/wsj_2078   0   12             .     .           *))          -    -   -   -   *         *        *        *   -

nw/wsj/20/wsj_2078   0    0          Other    JJ  (TOP(S(S(NP(NP*       -    -   -   -   *   (ARG1*   (ARG1*    (ARG1*   -
nw/wsj/20/wsj_2078   0    1     antibodies   NNS                *)      -    -   -   -   *        *)       *         *   -
nw/wsj/20/wsj_2078   0    2        sparked   VBN             (VP*    spark  01   1   -   *      (V*)       *         *   -
nw/wsj/20/wsj_2078   0    3             by    IN             (PP*       -    -   -   -   *   (ARG0*        *         *   -
nw/wsj/20/wsj_2078   0    4            the    DT             (NP*       -    -   -   -   *        *        *         *   -
nw/wsj/20/wsj_2078   0    5    preparation    NN             *))))      -    -   -   -   *        *)       *)        *   -
nw/wsj/20/wsj_2078   0    6            are   VBP             (VP*       be  01   -   -   *        *      (V*)        *   -
nw/wsj/20/wsj_2078   0    7             of    IN             (PP*       -    -   -   -   *        *   (ARG2*         *   -
nw/wsj/20/wsj_2078   0    8              a    DT          (NP(NP*       -    -   -   -   *        *        *         *   -
nw/wsj/20/wsj_2078   0    9           sort    NN                *)      -    -   -   -   *        *        *         *   -
nw/wsj/20/wsj_2078   0   10         rarely    RB           (ADJP*       -    -   -   -   *        *        *         *   -
nw/wsj/20/wsj_2078   0   11        present    JJ                *       -    -   -   -   *        *        *         *   -
nw/wsj/20/wsj_2078   0   12             in    IN             (PP*       -    -   -   -   *        *        *         *   -
nw/wsj/20/wsj_2078   0   13          large    JJ             (NP*       -    -   -   -   *        *        *         *   -
nw/wsj/20/wsj_2078   0   14     quantities   NNS               *))      -    -   -   -   *        *        *         *   -
nw/wsj/20/wsj_2078   0   15             in    IN             (PP*       -    -   -   -   *        *        *         *   -
nw/wsj/20/wsj_2078   0   16       infected    JJ        (NP(ADJP*       -    -   -   -   *        *        *         *   -
nw/wsj/20/wsj_2078   0   17             or    CC                *       -    -   -   -   *        *        *         *   -
nw/wsj/20/wsj_2078   0   18            ill    JJ                *)      -    -   -   -   *        *        *         *   -
nw/wsj/20/wsj_2078   0   19    individuals   NNS          *)))))))      -    -   -   -   *        *        *)        *)  -
nw/wsj/20/wsj_2078   0   20              ,     ,                *       -    -   -   -   *        *        *         *   -
nw/wsj/20/wsj_2078   0   21             he   PRP             (NP*)      -    -   -   -   *        *        *    (ARG0*)  -
nw/wsj/20/wsj_2078   0   22          added   VBD             (VP*)     add  01   -   -   *        *        *       (V*)  -
nw/wsj/20/wsj_2078   0   23              .     .               *))      -    -   -   -   *        *        *         *   -

nw/wsj/20/wsj_2078   0    0            One    CD   (TOP(S(NP(NP*)            -    -   -   -    (CARDINAL)  (ARG1*             *             *   -
nw/wsj/20/wsj_2078   0    1             of    IN            (PP*             -    -   -   -            *        *             *             *   -
nw/wsj/20/wsj_2078   0    2            the    DT         (NP(NP*             -    -   -   -            *        *             *             *   -
nw/wsj/20/wsj_2078   0    3      mysteries   NNS               *)            -    -   -   -            *        *             *             *   -
nw/wsj/20/wsj_2078   0    4             of    IN            (PP*             -    -   -   -            *        *             *             *   -
nw/wsj/20/wsj_2078   0    5           AIDS   NNP        (NP*)))))            -    -   -   -            *        *)            *             *   -
nw/wsj/20/wsj_2078   0    6        remains   VBZ            (VP*         remain  01   -   -            *      (V*)            *             *   -
nw/wsj/20/wsj_2078   0    7            why   WRB   (SBAR(WHADVP*)            -    -   -   -            *   (ARG3*    (ARGM-CAU*)   (ARGM-CAU*)  -
nw/wsj/20/wsj_2078   0    8       infected    JJ          (S(NP*             -    -   -   -            *        *        (ARG0*        (ARG1*   -
nw/wsj/20/wsj_2078   0    9         people   NNS               *)            -    -   -   -            *        *             *)            *)  -
nw/wsj/20/wsj_2078   0   10        produce   VBP         (VP(VP*        produce  01   -   -            *        *           (V*)            *   -
nw/wsj/20/wsj_2078   0   11          large    JJ         (NP(NP*             -    -   -   -            *        *        (ARG1*             *   -
nw/wsj/20/wsj_2078   0   12     quantities   NNS               *)            -    -   -   -            *        *             *             *   -
nw/wsj/20/wsj_2078   0   13             of    IN            (PP*             -    -   -   -            *        *             *             *   -
nw/wsj/20/wsj_2078   0   14     antibodies   NNS         (NP*))))            -    -   -   -            *        *             *)            *   -
nw/wsj/20/wsj_2078   0   15              ,     ,               *             -    -   -   -            *        *             *             *   -
nw/wsj/20/wsj_2078   0   16            but    CC               *             -    -   -   -            *        *             *             *   -
nw/wsj/20/wsj_2078   0   17    deteriorate   VBP            (VP*    deteriorate  01   1   -            *        *             *           (V*)  -
nw/wsj/20/wsj_2078   0   18    nonetheless    RB     (ADVP*))))))            -    -   -   -            *        *)            *    (ARGM-ADV*)  -
nw/wsj/20/wsj_2078   0   19              .     .              *))            -    -   -   -            *        *             *             *   -

#end document
